Twenty doses of outpatient HD-MTX with glucarpidase were administered to seven patients. After 20 of 20 (100%) treatments, serum MTX levels were reduced to <100 nmol/L. Treatments were well-tolerated, ...

The intracellular polyglutamation of methotrexate (MTX) is emerging as a crucial biochemical process in rheumatoid arthritis (RA) therapy. MTX polyglutamates (MTX-PGs) are metabolites formed by the ...

In July 2022, the US Food and Drug Administration (FDA) expanded the labeling of Krystexxa (pegloticase; Horizon Therapeutics), a PEGylated uric acid-specific enzyme, to include coadministration with ...

Please provide your email address to receive an email when new articles are posted on . The FDA has approved the supplemental biologics license application for pegloticase, expanding the drug’s label ...

The US Food and Drug Administration (FDA) has approved concomitant use of the biologic pegloticase (Krystexxa) and methotrexate to lower serum uric acid levels (sUA) in patients with chronic gout.

Indication(s): Chronic gout in adult patients refractory to conventional therapy. The expanded approval was based on data from the phase 4 MIRROR trial, which evaluated Krystexxa plus methotrexate in ...

Subcutaneous tocilizumab, either as monotherapy or in combination with methotrexate, demonstrated greater efficacy than methotrexate alone and was well tolerated in patients with active rheumatoid ...